Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WB006
- Development stage
- Preclinical
- Lead developer
- Bausch + Lomb
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
WB006 is an investigational drug initially developed by Whitecap Biosciences and now under the development of Bausch + Lomb following their acquisition of Whitecap Biosciences. The drug is in preclinical development, with its primary indication being geographic atrophy, a severe form of age-related macular degeneration that leads to vision loss. While specific details about the mechanism of action or molecular modality have not been disclosed publicly, WB006 is part of a pipeline focused on novel therapies for eye diseases such as glaucoma and geographic atrophy[1][2][4][6].
- Other names
- BL1107 sustained release implantBL-1107 sustained release implantBL 1107 sustained release implantBL1107 sustained-release implantBL-1107 sustained-release implantBL 1107 sustained-release implant
02
Targets
ADRA2A (α2A)ADRA2B (α2B)
Beyond the preview
Go deeper on WB006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WB006.